Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26098 | 1.00 | — | — | |
| SCHEMBL26191 | 0.97 | — | — | |
| SCHEMBL1259816 | 0.91 | — | — | |
| SCHEMBL6050112 | 0.84 | — | — | |
| SCHEMBL27619702 | 0.76 | CXCR4 (0.32) | — | |
| SCHEMBL4397792 | 0.73 | — | — | |
| SCHEMBL28634 | 0.72 | — | — | |
| SCHEMBL4142612 | 0.72 | CA12 (0.41) | HTT | |
| SCHEMBL27359 | 0.72 | — | — | |
| SCHEMBL22207636 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0457195-B1 | Peptides having endothelin antagonist activity, a process for preparation thereof and pharmaceutical compositions comprising the same | FUJISAWA PHARMACEUTICAL CO (JP) | 1998-04-15 | — | — | EP | claimed |
| US-5656604-A | HYPOTENSIVE AGENT; ENDOTHELIN ANTAGONIST | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1997-08-12 | — | — | US | claimed |
| US-5430022-A | Endothelin antagonists; hypotensive agents; treatment for angina pectoris, brain disorders, asthma, renal failure | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1995-07-04 | — | — | US | claimed |
| US-5284828-A | Hypotensive agents | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 1994-02-08 | — | — | US | claimed |
| EP-0457195-A2 | Peptides having endothelin antagonist activity, a process for preparation thereof and pharmaceutical compositions comprising the same | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1991-11-21 | — | — | EP | claimed |
| CN-113226310-B | 15-PGDH inhibitors | 杏林制药株式会社 | 2024-03-19 | — | — | CN | disclosed |
| US-20230082516-A1 | 15-PGDH INHIBITOR | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2023-03-16 | — | — | US | disclosed |
| US-11365192-B2 | Pyridine compound substituted with azole | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2022-06-21 | — | — | US | disclosed |
| EP-3922247-A1 | 15-PGDH INHIBITOR | Kyorin Pharmaceutical Co., Ltd. (JP) | 2021-12-15 | — | — | EP | disclosed |
| EP-3917911-A1 | 15-PGDH INHIBITORS | Kyorin Pharmaceutical Co., Ltd. (JP) | 2021-12-08 | — | — | EP | disclosed |
| CN-113226310-A | 15-PGDH inhibitors | 杏林制药株式会社 | 2021-08-06 | — | — | CN | disclosed |
| US-20210122741-A1 | PYRIDINE COMPOUND SUBSTITUTED WITH AZOLE | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2021-04-29 | — | — | US | disclosed |
| EP-0457195-B1 | Peptides having endothelin antagonist activity, a process for preparation thereof and pharmaceutical compositions comprising the same | FUJISAWA PHARMACEUTICAL CO (JP) | 1998-04-15 | — | — | EP | disclosed |
| US-5656604-A | HYPOTENSIVE AGENT; ENDOTHELIN ANTAGONIST | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1997-08-12 | — | — | US | disclosed |
| US-5514676-A | TO INHIBIT THE FORMATION OF ADVANCED GLYCOSLYATION PRODUCTS BY THE NONENZYMATIC CROSSLINKING OF PROTEINS WITH REDUCING SUGARS, USED IN FOOD PRESERVATION AND TO PREVENT PROTEIN AGING IN COLLAGEN OR LENSES IN THE EYE PRESERVATION | THE ROCKEFELLER UNIVERSITY (US) | 1996-05-07 | — | — | US | disclosed |
| EP-0706532-A1 | NEW COMPOUND AND ITS PREPARATION | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1996-04-17 | — | — | EP | disclosed |
| US-5430022-A | Endothelin antagonists; hypotensive agents; treatment for angina pectoris, brain disorders, asthma, renal failure | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1995-07-04 | — | — | US | disclosed |
| WO-1995000537-A1 | NEW COMPOUND AND ITS PREPARATION | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1995-01-05 | — | — | WO | disclosed |
| US-5284828-A | Hypotensive agents | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 1994-02-08 | — | — | US | disclosed |
| EP-0457195-A2 | Peptides having endothelin antagonist activity, a process for preparation thereof and pharmaceutical compositions comprising the same | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1991-11-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210122741-A1 | PYRIDINE COMPOUND SUBSTITUTED WITH AZOLE | CYP2C19, CYP4A11, CYP11B1 | HTT 4396/4885 |
| US-20230082516-A1 | 15-PGDH INHIBITOR | UGDH, HPGD, GCDH | HTT 4567/4885 |
| US-11365192-B2 | Pyridine compound substituted with azole | CYP2C19, CYP4A11, CYP11B1 | HTT 4396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.